Sania Kothari

Intellia Therapeutics is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. We are employing our proprietary technologies to create diverse therapeutic approaches spanning a range of diseases to realize Intellia’s full potential and address the needs of patients globally. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/. Intellia Therapeutics, and the Intellia Therapeutics logo are trademarks of Intellia Therapeutics, Inc., registered in the U.S. Patent and Trademark Office and other jurisdictions. © 2026. Intellia Therapeutics, Inc.